Research Grade Litifilimab

Catalog No.

DHJ29001

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Humanized

Isotype

IgG1-kappa

Clonality

Monoclonal

Target

CLEC4C, C-type lectin superfamily member 7, CLECSF11, C-type lectin domain family 4 member C, Dendritic lectin, CD303, DLEC, HECL, Blood dendritic cell antigen 2, BDCA-2, BDCA2, CLECSF7

Concentration

3.45 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q8WTT0

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

BIIB 059, BIIB-059, BIIB059, CAS: 2407378-48-5

Clone ID

Litifilimab

Pharmacodynamic Effects of Litifilimab in Lupus in the LILAC Phase II Study: Rapid and Sustained Reductions in Type I Interferon-Associated Gene Expression and Cytokines., PMID:40488251

An Integrative Mechanistic Model of Type 1 IFN-Mediated Inflammation in Systemic Lupus Erythematosus., PMID:40364448

RF - New Treatments in Cutaneous Lupus Erythematosus: Current and Future Perspectives., PMID:40204141

A focused report on IFN-1 targeted therapies for lupus erythematosus., PMID:40047795

Part B of the LILAC study of litifilimab for cutaneous lupus erythematosus: a plain language summary., PMID:39995069

Part A of the LILAC study of litifilimab for systemic lupus erythematosus: a plain language summary., PMID:39995062

Evolving Treatment Strategies for Systemic Lupus Erythematosus in Clinical Practice: A Narrative Review., PMID:39759646

Deucravacitinib shows superior efficacy and safety in cutaneous lupus erythematosus compared to various biologics and small molecules - A systematic review and meta-analysis., PMID:39694128

An update on clinical trials for cutaneous lupus erythematosus., PMID:38491743

Emerging biologic therapies for systemic lupus erythematosus., PMID:38299618

The development of litifilimab (BIIB 059) for cutaneous and systemic lupus erythematosus., PMID:37877249

Emerging immunotherapeutic strategies for cutaneous lupus erythematosus: an overview of recent phase 2 and 3 clinical trials., PMID:37860982

Litifilimab (BIIB059), a promising investigational drug for cutaneous lupus erythematosus., PMID:37148249

Cutaneous Lupus Erythematosus: An Update on Pathogenesis and Future Therapeutic Directions., PMID:37140884

Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus., PMID:36069871

Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus., PMID:35939578

Document Download

Research Grade Litifilimab.pdf